May 28, 2019 08:16 AM EDTUpdated 01:14 PM
R&D

Analy­sis shows The Med­i­cines Com­pa­ny/Al­ny­lam drug in­clisir­an safe for re­nal­ly-im­paired pa­tients

Natalie Grover

Reporter

About a week af­ter long-term Phase II da­ta on The Med­i­cines Com­pa­ny’s $MD­CO Al­ny­lam

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

Up­dat­ed: Sage's roller coast­er ends in $561M ac­qui­si­tion by Su­per­nus

What's com­ing in five years? FDA chief points to uni­ver­sal flu vac­cine, new ap­proval path­way

Iso­mor­phic to open US of­fice in Cam­bridge, hires ex-Re­lay CMO

Im­muneer­ing says MEK pill beats stan­dard of care in first-line pan­cre­at­ic can­cer

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times